The 26 references in paper И. Таран Н., Т. Мартынюк В., С. Наконечников Н., И. Чазова Е. (2016) “ИННОВАЦИЯ В МЕДИКАМЕНТОЗНОМ ЛЕЧЕНИИ ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ ТРОМБОЭМБОЛИЧЕСКОЙ ЛЕГОЧНОЙ ГИПЕРТЕНЗИЕЙ: СТИМУЛЯТОР РАСТВОРИМОЙ ГУАНИЛАТЦИКЛАЗЫ — РИОЦИГУАТ” / spz:neicon:aterotromboz:y:2016:i:2:p:14-26

1
Kim NH, Delcroix M, Jenkins DP et al. Chronic Thromboembolic Pulmonary Hypertension. J Am CollCardiol, 2013, 62(Suppl): 92-99.
(check this in PDF content)
2
Чазова И.Е., Авдеев С.Н., Царева Н.А., Мартынюк Т.В., Волков А.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический архив, 2014, 9: 4–23.
(check this in PDF content)
3
Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation. Eur Heart J, 2009, 30(20): 2493-537.
(check this in PDF content)
4
Легочная гипертензия. Под ред. И.Е. Чазовой, Т.В. Мартынюк. М.: Практика, 2015. С. 563-605.
(check this in PDF content)
5
Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med, 2001, 345: 1465-72.
(check this in PDF content)
6
Чазова И.Е., Мартынюк Т.В., Чернявский А.М., Мершин К.В., Данилов Н.М., Матчин Ю.Г. Федеральные клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии, 2015, 35-44.
(check this in PDF content)
7
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Riociguat (Adempas): Management of Inoperable Chronic Thromboembolic Pulmonary Hypertension, 2015 Jul.
(check this in PDF content)
8
Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol, 2011, 154: 54-60.
(check this in PDF content)
9
Freed DH, Thomson BM, Berman M et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg, 2011, 141: 383-387.
(check this in PDF content)
10
Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. EurRespir Rev,2009, 18: 24-28.
(check this in PDF content)
11
Mayer E, Jenkins D, Lindner J et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg, 2011, 141: 702-710.
(check this in PDF content)
12
Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med., 2011, 364: 351-360.
(check this in PDF content)
13
Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med, 1995, 333: 214-21.
(check this in PDF content)
14
Stasch JP, Pacher P, Evgenov OV. Soluble guanylatecyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 2011, 123: 2263-2273.
(check this in PDF content)
15
Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest, 2004, 125: 580-586.
(check this in PDF content)
16
Mittendorf J, Weigand S, Alonso-Alij C. Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble GuanylateCyclase for the Treatment of Pulmonary Hypertension. Chem Med Chem, 2009 May 11, 4(Issue 5): 853-865.
(check this in PDF content)
17
Grimminger F, Weimann G, Frey R et al. First acute haemodynamic study of soluble guanylatecyclase stimulator riociguat in pulmonary hypertension. Eur Respir J, 2009, 33: 785-92.
(check this in PDF content)
18
Lang M et al. The soluble guanylatecyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.BMC Pharmacology, 2011, 11(Suppl 1): P43.
(check this in PDF content)
19
Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE et al. Soluble guanylatecyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation,2004, 110: 2253-2259.
(check this in PDF content)
20
Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K et al. Activation of soluble guanylatecyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation, 2006 Jan 17, 113 (2): 286-295.
(check this in PDF content)
21
Ghofrani HA et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J, 2010, 36: 792-799.
(check this in PDF content)
22
Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med, 2013, 369: 319-29.
(check this in PDF content)
23
Simonneau G, D’Armini AM, Ghofrani HA et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J,2015 May, 45(5): 1293302.
(check this in PDF content)
24
Minai OA, Bonner N, Mathai SC, Busse D et al. Assessment Of Patient-Reported Health Status In Chronic Thromboembolic Pulmonary Arterial Hypertension Patients Treated With Riociguat: 2-Year Results From The Chest-2 Extension Study. Value Health, 2015 Nov, 18(7): A398-9.
(check this in PDF content)
25
Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, GaliП N. Treatment of pulmonary hypertension. Lancet Respir Med, 2016 Apr, 4 (4): 323-36.
(check this in PDF content)
26
Simonneau G, D’Armini AM, Ghofrani H-A et al. Latebreaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension. Eur Respir J,2014 Sep, 44(Suppl 58). Link:
(check this in PDF content)